Obermatt
See Similar Stocks →

Prothena Corporation

NSQ:PRTA · IE00B91XRN20
BiotechnologySmall

360

39
Profit price34
Owner Earnings Yield1
Dividend Yield1
Price/Sales24
Price/Book45
Return on Capital64
Cash Return on Capital45
Return on Equity60
EBIT Margin15
Gross Profitability23
Accruals77
Owner Earnings Margin28
Sales growth89
Profit growth31
Reinvestment67
Price momentum83
Debt load74
Refinancing18
Debt Payback1
Liquidity21
Analyst ratings5
Opinion Changes50
Price Target Upside75
Market mood43
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Prothena Corporation doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryIreland
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2012
Employees76
Websiteprothena.com
ISINIE00B91XRN20
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
ImmunologyVaccinesNeuroscienceChronic DiseasesNeurologyCentral Nervous SystemBiotechnologyHealth CareScience and Engineering

Description

Prothena Corporation plc (Prothena) operates as a late-stage clinical biotechnology company. The company has expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neu…

Analysis

Middle-of-the-road

Prothena Corporation plc is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is solid and the balance sheet is stretched. The company scores 6/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
53
2026

All-time high

53

Jun 2026

All-time low

28

Mar 2026

Average rank

41

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
24
—
—
—
Price/Earnings
78
—
—
—
Price/Book
45
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
45
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Prothena Corporation with its peers
AC Immune
NMQ:ACIU
68
CountrySwitzerland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Immunocore
NSQ:IMCR
40
CountryUK
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Inventiva
PAR:IVA
16
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Mereo BioPharma Group
NAQ:MREO
51
CountryUK
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
BeOne Medicines
SHH:688235
91
CountrySwitzerland
IndustryBiotechnology
SizeX-Large
Full Stock Analysis →
Innate Pharma
PAR:IPH
54
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →